VENITI, Inc., a company dedicated to providing innovative technology for the treatment of venous disease, announced that it has received approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the VIRTUS trial of the VENITI VICI Venous Stent System. The VICI Venous Stent System was designed from inception to be compatible with the unique anatomy and pathophysiology of the venous system. Hundreds of thousands of people around the world suffer from lower-extremity venous disease, and until recently, the only treatment options available involved the use of re-purposed vascular stents originally designed for use in the arterial system.
The Cardiac Science Powerheart® G5 is the first Automated External Defibrillator to combine real-time CPR feedback, fully automatic shock delivery, variable escalating energy, and fast shock times. The powerful capabilities of the Powerheart G5 AED enable rescue professionals and lay responders to administer therapy in a timely and effective manner to give a victim of sudden cardiac arrest the best chance of survival.
Anetic Aid equipment is no stranger to the large or small screen. The QA3 and QA4 trolley systems and tourniquets are frequently seen in documentaries that feature real hospitals, in news footage and as props in many dramas.
S20, the newest high-end color Doppler trolley system from SonoScape, is specially designed for full ultrasound applications, including Radiology, Cardiovascular, OB/GYN and others. This is the first trolley system that has a perfect combination of 17” wide monitor and 10.4” touch panel. Its innovative ergonomic design, excellent performance, and latest ultrasound technology make S20 to be a superstar in the trolley family.
Pro-Lab Diagnostics has released a rapid visual assay for the detection of H. pylori in faecal samples. PYLORITOP® Ag+ is an immunochromatogenic test designed to provide clinical laboratories with a cost-effective assay to help meet current guidelines for
Pro-Lab Diagnostics has released a rapid visual assay for the detection of H. pylori in faecal samples. PYLORITOP® Ag+ is an immunochromatogenic test designed to provide clinical laboratories with a cost-effective assay to help meet current guidelines for the detection and treatment of H. pylori 1.
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, announced today that it has entered into an exclusive licensing agreement with Inven2, the technology transfer office at Oslo University Hospital (OUS) and University of Oslo (UiO), for 12 highly promising colorectal cancer tissue biomarkers.
NUFFIELD HEALTH PATIENTS CAN NOW BENEFIT FROM INDIVIDUA Treatment Planning For Early Stage Breast Cancer
Increased access to Genomic Health’s Oncotype DX test helps predict risk of recurrence and chemotherapy benefit, sparing women in the UK from unnecessary chemotherapy treatment
BMI The Alexandra Hospital is the first hospital in the North West to provide a new, non-surgical treatment for liver cancer. The DEBIRI (Drug-Eluting Beads delivering Irinotecan) treatment is for patients suffering from both primary, where the disease originated in the liver or secondary liver cancer – where it travelled to the liver from another organ such as the bowel or breast.The DEBIRI treatment is minimally invasive and treats patients who have inoperable tumours by shrinking them and making surgery possible.
A new line of 405nm-excited fluorochrome conjugated antibodies for flow cytometry
iCyt Mission Technology, Inc. (iCyt), a wholly-owned subsidiary of Sony Corporation of America, has announced the introduction of its new line of 405nm-excited fluorochrome conjugated antibodies for flow cytometry. These new Brilliant Violet™ 421 products are part of the first commercial release of a novel, polymer-based fluorophore technology.
Special Needs Fitness Guru Suzanne M. Gray Releases New Book on World Autism Awareness Day: Shows Ways to Improve Health and Socialization Skills
More than half of children with autism spectrum disorders are overweight, at risk for diabetes or cardiovascular disease,
Page 6 of 23